1 Introduction (Page No. – 15)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Markets Covered
1.3.1 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders
2 Research Methodology (Page No. – 18)
2.1 Research Methodology Steps
2.2 Secondary and Primary Research Methodology
2.2.1 Secondary Research
2.2.1.1 Key Data From Secondary Sources
2.2.2 Primary Research
2.2.2.1 Breakdown of Primaries
2.2.2.2 Key Data From Primary Sources
2.3 Market Size Estimation
2.3.1 Research Methodology: Bottom-Up Approach
2.3.2 Research Methodology: Top-Down Approach
2.4 Market Breakdown and Data Triangulation
3 Executive Summary (Page No. – 26)
3.1 Introduction
3.2 Evolution
3.3 Current Scenario
3.4 Future Outlook
3.5 Conclusion
4 Premium Insights (Page No. – 32)
4.1 Global Cardiac Marker Testing Market Overview
4.2 Geographic Analysis: Cardiac Marker Testing Market, By Technology, 2016
4.3 Market Size, By Type, 2016 vs 2021
4.4 Market, By Product, 2016 vs 2021
4.5 Geographical Snapshot of the Market, 2016
4.6 Life Cycle Analysis, By Region
5 Market Overview (Page No. – 37)
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Growing Incidences of Cardiovascular Diseases
5.2.1.2 Rapidly Increasing Geriatric Population and the Subsequent Increase in the Burden of Heart Diseases Worldwide
5.2.1.3 Growing Funding From Public–Private Organizations for Research on Cardiac Biomarkers
5.2.1.4 Ongoing Clinical Trials for Identification of Novel Cardiac Biomarkers
5.2.2 Restraints
5.2.2.1 Technical Problems Related to Sample Collection and Storage
5.2.2.2 Issues Related to Regulatory and Reimbursement Systems
5.2.3 Opportunities
5.2.3.1 Point-Of-Care Testing (Poct) With Cardiac Biomarkers
5.2.3.2 Emerging Markets to Offer New Growth Avenues for Market Players
6 Industry Insights (Page No. – 44)
6.1 Introduction
6.2 Value Chain Analysis
6.3 Industry Trends
6.3.1 Ongoing Research on Novel Cardiac Biomarkers for Cardiovascular Diseases
6.3.2 Combination of Various Cardiac Biomarkers to Improve Patient Management
6.3.3 Development of High-Sensitivity Troponin Assays
6.4 Porter’s Five Forces Analysis
6.4.1 Threat of New Entrants
6.4.2 Threat of Substitutes
6.4.3 Bargaining Power of Suppliers
6.4.4 Bargaining Power of Buyers
6.4.5 Intensity of Competitive Rivalry
7 Cardiac Marker Testing Market, By Type (Page No. – 52)
7.1 Introduction
7.2 Troponin I and T
7.3 CK-MB
7.4 Bnp Or Nt-Probnp
7.5 Myoglobin
7.6 Hscrp
7.7 Other Biomarkers
8 Cardiac Marker Testing Market, By Product (Page No. – 65)
8.1 Introduction
8.2 Reagents and Kits
8.3 Instruments
8.3.1 Chemiluminescence
8.3.2 Immunofluorescence
8.3.3 Elisa
8.3.4 Immunochromatography
9 Cardiac Marker Testing Market, By Disease (Page No. – 77)
9.1 Introduction
9.2 Myocardial Infarction
9.3 Congestive Heart Failure
10 Cardiac Marker Testing Market, By Type of Testing (Page No. – 83)
10.1 Introduction
10.2 Laboratory Testing
10.3 Point-Of-Care Testing
11 Cardiac Marker Testing Market, By Region (Page No. – 89)
11.1 Introduction
11.2 North America
11.2.1 U.S.
11.2.1.1 Growing Prevalence of Cardiovascular Diseases
11.2.1.2 Increasing Public-Private Investments on Cardiac Biomarker Research
11.2.1.3 Rising Geriatric & Obese Population
11.2.1.4 Nih Support for the Development of Cardiac Biomarkers
11.2.2 Canada
11.2.2.1 Rising Incidence of Cardiovascular Diseases
11.2.2.2 Increasing Government Investments
11.3 Europe
11.3.1 Rising Incidence of CVD
11.3.2 Increasing Number of Conferences and Symposiums
11.3.3 Rising Partnerships and Collaborations for the Development of Cardiac Biomarkers
11.3.4 Increasing Government Investments to Develop Novel Cardiac Biomarkers
11.4 Asia-Pacific
11.4.1 Increasing Incidence of CVD
11.4.2 Increasing Awareness Due to Going Conferences and Initiatives Taken By Market Players
11.4.3 Government Investments Towards Cardiac Biomarker Research
11.5 Rest of the World
12 Competitive Landscape (Page No. – 114)
12.1 Introduction
12.2 Strategic Overview
12.3 Leading Players in the Market
12.4 Competitive Situation and Trends
12.4.1 Product Launches, Approvals, and Showcases
12.4.2 Agreements and Partnerships
12.4.3 Acquisitions
12.4.4 Other Developments
13 Company Profiles (Page No. – 120)
(Overview, Products and Services, Financials, Strategy & Development)*
13.1 Introduction
13.2 Roche Diagnostics Limited (A Subsidiary of F. Hoffman-LA Roche Ltd.)
13.3 Abbott Laboratories
13.4 Siemens AG
13.5 Danaher Corporation
13.6 Biomérieux SA
13.7 Alere Inc.
13.8 LSI Medience Corporation (A Subsidiary 0f Mitsubishi Chemical Holdings Corporation)
13.9 Ortho Clinical Diagnostics (A Subsidiary of the Carlyle Group)
13.10 Randox Laboratories Ltd.
13.11 Guangzhou Wondfo Biotech Co., Ltd.
*Details on Overview, Products and Services, Financials, Strategy & Development Might Not Be Captured in Case of Unlisted Companies.
14 Appendix (Page No. – 140)
14.1 Insights of Industry Experts
14.2 Discussion Guide
14.3 Knowledge Store: Marketsandmarkets’ Subscription Portal
14.4 Introducing RT: Real-Time Market Intelligence
14.5 Available Customizations
14.6 Related Reports
Table 1 Cardiac Marker Testing Market Size, By Type, 2014–2021 (USD Million)
Table 2 Characteristics of Troponin Cardiac Marker
Table 3 Market Size for Troponin I and T, By Region, 2014–2021 (USD Million)
Table 4 North America: Market Size Troponin I and T, By Country, 2014–2021 (USD Million)
Table 5 Characteristics of CK-MB Cardiac Marker
Table 6 Market Size for CK-MB, By Region, 2014–2021 (USD Million)
Table 7 North America: Market Size CK-MB, By Country, 2014–2021 (USD Million)
Table 8 Market Size for Bnp Or Nt-Probnp, By Region, 2014–2021 (USD Million)
Table 9 North America: Market Size Bnp Or Nt-Probnp, By Country, 2014–2021 (USD Million)
Table 10 Characteristics of Myoglobin Cardiac Marker
Table 11 Market Size for Myoglobin, By Region, 2014–2021 (USD Million)
Table 12 North America: Market Size for Myoglobin, By Country, 2014–2021 (USD Million)
Table 13 Cut-Offs for CRP Using Standardized Assay
Table 14 Market Size for Hscrp, By Region, 2014–2021 (USD Million)
Table 15 North America: Market Size for Hscrp, By Country, 2014–2021 (USD Million)
Table 16 Market Size for Other Biomarkers, By Region, 2014–2021 (USD Million)
Table 17 North America: Market Size for Other Biomarkers, By Country, 2014–2021 (USD Million)
Table 18 Market Size, By Product, 2014–2021 (USD Million)
Table 19 Cardiac Marker Testing Reagents and Kits Market Size, By Region, 2014–2021 (USD Million)
Table 20 North America: Cardiac Marker Testing Reagents & Kits Market Size, By Country, 2014–2021 (USD Million)
Table 21 Cardiac Marker Testing Instruments Market Size, By Region, 2014–2021 (USD Million)
Table 22 North America: Cardiac Marker Testing Instruments Market Size, By Country, 2014–2021 (USD Million)
Table 23 Cardiac Marker Testing Instruments Market Size, By Method, 2014–2021 (USD Million)
Table 24 Cardiac Marker Testing Instruments Market Size for Chemiluminescence, By Region, 2014–2021 (USD Million)
Table 25 North America: Cardiac Marker Testing Instruments Market Size for Chemiluminescence, By Country, 2014–2021 (USD Million)
Table 26 Cardiac Marker Testing Instruments Market Size for Immunofluorescence, By Region, 2014–2021 (USD Million)
Table 27 North America: Cardiac Marker Testing Instruments Market Size for Immunofluorescence, By Country, 2014–2021 (USD Million)
Table 28 Cardiac Marker Testing Instruments Market Size for Elisa, By Region, 2014–2021 (USD Million)
Table 29 North America: Cardiac Marker Testing Instruments Market Size for Elisa, By Country, 2014–2021 (USD Million)
Table 30 Cardiac Marker Testing Instruments Market Size for Immunochromatography, By Region, 2014–2021 (USD Million)
Table 31 North America: Cardiac Marker Testing Instruments Market Size for Immunochromatography, By Country, 2014–2021 (USD Million)
Table 32 Market Size, By Disease, 2014–2021 (USD Million)
Table 33 Market Size for Myocardial Infarction, By Region, 2014–2021 (USD Million)
Table 34 North America: Market Size for Myocardial Infarction, By Country, 2014–2021 (USD Million)
Table 35 Market Size for Congestive Heart Failure, By Region, 2014–2021 (USD Million)
Table 36 North America: Market Size for Congestive Heart Failure, By Country, 2014–2021 (USD Million)
Table 37 Market Size, By Type of Testing, 2014–2021 (USD Million)
Table 38 Cardiac Marker Laboratory Testing Market Size, By Region, 2014–2021 (USD Million)
Table 39 North America: Cardiac Marker Laboratory Testing Market Size, By Country, 2014–2021 (USD Million)
Table 40 Cardiac Marker Point-Of-Care Testing Market Size, By Region, 2014–2021 (USD Million)
Table 41 North America: Cardiac Marker Point-Of-Care Testing Market Size, By Country, 2014–2021 (USD Million)
Table 42 Market Size, By Region, 2014-2021 (USD Million)
Table 43 North America: Market Size, By Country, 2014–2021 (USD Million)
Table 44 North America: Market Size, By Type, 2014–2021 (USD Million)
Table 45 North America: Market Size, By Product, 2014–2021 (USD Million)
Table 46 North America: Market Size, By Disease, 2014–2021 (USD Million)
Table 47 North America: Market Size, By Type of Testing, 2014–2021 (USD Million)
Table 48 U.S.: Market Size, By Type, 2014–2021 (USD Million)
Table 49 U.S.: Market Size, By Product, 2014–2021 (USD Million)
Table 50 U.S.: Market Size, By Disease, 2014–2021 (USD Million)
Table 51 U.S.: Market Size, By Type of Testing, 2014–2021 (USD Million)
Table 52 Canada: Market Size, By Type, 2014–2021 (USD Million)
Table 53 Canada: Market Size, By Product, 2014–2021 (USD Million)
Table 54 Canada: Market Size, By Disease, 2014–2021 (USD Million)
Table 55 Canada: Market Size, By Type of Testing, 2014–2021 (USD Million)
Table 56 Europe: Market Size, By Type, 2014–2021 (USD Million)
Table 57 Europe: Market Size, By Product, 2014–2021 (USD Million)
Table 58 Europe: Market Size, By Disease, 2014–2021 (USD Million)
Table 59 Europe: Market Size, By Type of Testing, 2014–2021 (USD Million)
Table 60 Asia-Pacific: Market Size, By Type, 2014–2021 (USD Million)
Table 61 Asia-Pacific: Market Size, By Product, 2014–2021 (USD Million)
Table 62 Asia-Pacific: Market Size, By Disease, 2014–2021 (USD Million)
Table 63 Asia-Pacific: Market Size, By Type of Testing, 2014–2021 (USD Million)
Table 64 RoW: Market Size, By Type, 2014–2021 (USD Million)
Table 65 RoW: Market Size, By Product, 2014–2021 (USD Million)
Table 66 RoW: Market Size, By Disease, 2014–2021 (USD Million)
Table 67 RoW: Market Size, By Type of Testing, 2014–2021 (USD Million)
Table 68 Product Launches, Approvals, and Showcases, 2013–2016
Table 69 Agreements and Partnerships, 2013-2016
Table 70 Acquisitions, 2013–2016
Table 71 Other Developments, 2013–2016
List of Figures (44 Figures)
Figure 1 Global Cardiac Marker Testing Market: Research Methodology Steps
Figure 2 Breakdown of Supply-Side Primary Interviews: By Company Type, Designation, and Region
Figure 3 Research Design
Figure 4 Market: Data Triangulation
Figure 5 Evolution of Cardiac Biomarkers
Figure 6 Market Size, By Type, 2016 vs 2021 (USD Million)
Figure 7 Global Market Size, By Product, 2016 vs 2021 (USD Million)
Figure 8 Global Market Size, By Disease, 2016 vs 2021 (USD Million)
Figure 9 Global Market Size, By Type of Testing, 2016 vs 2021 (USD Million)
Figure 10 Global Market, By Region, 2016
Figure 11 Increasing Incidences of Cardiovascular Diseases Across the Globe are Driving Growth in the Market
Figure 12 Troponin I and T to Dominate the Market in 2016
Figure 13 Reagents and Kits to Continue to Dominate the Market During the Forecast Period
Figure 14 Asia-Pacific to Witness Highest Growth During the Forecast Period
Figure 15 Asia-Pacific Holds Lucrative Growth Opportunities
Figure 16 Market: Drivers, Restraints, Opportunities, and Challenges
Figure 17 Market: Value Chain Analysis
Figure 18 Porter’s Five Forces Analysis 2016
Figure 19 Market Segmentation, By Type
Figure 20 Market Size, By Type, 2016-2021
Figure 21 Market Segmentation, By Product
Figure 22 Market Size, By Product, 2016 (USD Million)
Figure 23 Cardiac Marker Testing Market Segmentation, By Disease
Figure 24 Cardiac Marker Testing Market Size, By Disease, 2016 (USD Million)
Figure 25 Prevalence of Congestive Heart Failure, 2014
Figure 26 Cardiac Marker Testing Market Segmentation, By Type of Testing
Figure 27 Cardiac Marker Testing Market Size, By Type of Testing, 2016 (USD Million)
Figure 28 Cardiac Marker Testing Market, By Region
Figure 29 Asia-Pacific to Grow at the Highest Rate During the Forecast Period
Figure 30 North America: Cardiac Marker Testing Market Snapshot
Figure 31 Europe: Cardiac Marker Testing Market Snapshot
Figure 32 Asia-Pacific: Cardiac Marker Testing Market Snapshot
Figure 33 RoW: Cardiac Marker Testing Market Snapshot
Figure 34 Key Growth Strategies Adopted By Market Players From 2013 to 2016
Figure 35 Rank of Key Players in the Global Cardiac Marker Testing Market, 2015
Figure 36 Product Launches and Showcases—Majorly Adopted Growth Strategy By Market Players From 2013 to 2016
Figure 37 Financial Performance of the Top 6 Market Players in 2015
Figure 38 Roche Diagnostics Limited: Company Snapshot
Figure 39 Abbott Laboratories: Company Snapshot
Figure 40 Siemens AG: Company Snapshot
Figure 41 Danaher Corporation: Company Snapshot
Figure 42 Biomérieux SA: Company Snapshot
Figure 43 Alere Inc.: Company Snapshot
Figure 44 Mitsubishi Chemical Holdings Corporation: Company Snapshot
【レポートのキーワード】
心疾患マーカー検査、トロポニンI&T、CK-MB、ミオグロビン、BNP、hsCRP、化学発光、心疾患マーカー試薬、装置、慰労機器、心筋梗塞、うっ血性心不全
